APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Peptide

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Therapeutic Peptide Market Outlook and Growth Opportunities 2026

31 December 2025198 pages

Choose your research edition.

Industry ResearchTherapeutic Peptide Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Peptide Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Therapeutic Peptide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Peptide Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Peptide Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Therapeutic Peptide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Therapeutic Peptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Peptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Peptide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Therapeutic Peptide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Therapeutic Peptide market include Takeda, Teva, Sanofi, Johnson and Johnson, Novartis, Novo Nordisk, Merck, Eli Lilly and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Therapeutic Peptide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Peptide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Peptide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Therapeutic Peptide market size, projected growth trends, production technologies, key applications, and end-use industries.

Therapeutic Peptide Segment by Company

Takeda

Teva

Sanofi

Johnson and Johnson

Novartis

Novo Nordisk

Merck

Eli Lilly

AbbVie

AstraZeneca

Ipsen

Therapeutic Peptide Segment by Type

Oral

Injection

Other

Therapeutic Peptide Segment by Application

Central Nervous System

Metabolic Disorders

Cancer

Other

Therapeutic Peptide Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Therapeutic Peptide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Therapeutic Peptide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Therapeutic Peptide significant trends, drivers, influence factors in global and regions.

6. To analyze Therapeutic Peptide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Therapeutic Peptide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Peptide industry.

Chapter 3: Detailed analysis of Therapeutic Peptide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Therapeutic Peptide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Therapeutic Peptide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Peptide Industry Trends Table 2. Therapeutic Peptide Industry Drivers Table 3. Therapeutic Peptide Industry Opportunities and Challenges Table 4. Therapeutic Peptide Industry Restraints Table 5. Global Therapeutic Peptide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Therapeutic Peptide Revenue Share by Company (2021-2026) Table 7. Global Therapeutic Peptide Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Therapeutic Peptide Sales Volume Share by Company (2021-2026) Table 9. Global Therapeutic Peptide Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Therapeutic Peptide Company Ranking, (2024-2026) & (USD Million) Table 11. Global Therapeutic Peptide Key Company Manufacturing Base & Headquarters Table 12. Global Therapeutic Peptide Company, Product Type & Application Table 13. Global Therapeutic Peptide Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Therapeutic Peptide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Injection Table 19. Significant Companies of Other Table 20. Global Therapeutic Peptide Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Therapeutic Peptide Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Therapeutic Peptide Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Therapeutic Peptide Sales Volume Share by Type (2021-2026) Table 24. Global Therapeutic Peptide Sales Volume Share by Type (2027-2032) Table 25. Global Therapeutic Peptide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Therapeutic Peptide Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Therapeutic Peptide Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Therapeutic Peptide Sales Value Share by Type (2021-2026) Table 29. Global Therapeutic Peptide Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Central Nervous System Table 31. Significant Companies of Metabolic Disorders Table 32. Significant Companies of Cancer Table 33. Significant Companies of Other Table 34. Global Therapeutic Peptide Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Therapeutic Peptide Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Therapeutic Peptide Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Therapeutic Peptide Sales Volume Share by Application (2021-2026) Table 38. Global Therapeutic Peptide Sales Volume Share by Application (2027-2032) Table 39. Global Therapeutic Peptide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Therapeutic Peptide Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Therapeutic Peptide Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Therapeutic Peptide Sales Value Share by Application (2021-2026) Table 43. Global Therapeutic Peptide Sales Value Share by Application (2027-2032) Table 44. Global Therapeutic Peptide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Therapeutic Peptide Sales by Region (2021-2026) & (K Units) Table 46. Global Therapeutic Peptide Sales Market Share by Region (2021-2026) Table 47. Global Therapeutic Peptide Sales by Region (2027-2032) & (K Units) Table 48. Global Therapeutic Peptide Sales Market Share by Region (2027-2032) Table 49. Global Therapeutic Peptide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Therapeutic Peptide Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Therapeutic Peptide Sales Value Share by Region (2021-2026) Table 52. Global Therapeutic Peptide Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Therapeutic Peptide Sales Value Share by Region (2027-2032) Table 54. Global Therapeutic Peptide Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Therapeutic Peptide Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Therapeutic Peptide Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Therapeutic Peptide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Therapeutic Peptide Sales by Country (2021-2026) & (K Units) Table 59. Global Therapeutic Peptide Sales Market Share by Country (2021-2026) Table 60. Global Therapeutic Peptide Sales by Country (2027-2032) & (K Units) Table 61. Global Therapeutic Peptide Sales Market Share by Country (2027-2032) Table 62. Global Therapeutic Peptide Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Therapeutic Peptide Sales Value Market Share by Country (2021-2026) Table 64. Global Therapeutic Peptide Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Therapeutic Peptide Sales Value Market Share by Country (2027-2032) Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Takeda Therapeutic Peptide Product Portfolio Table 70. Takeda Recent Development Table 71. Teva Company Information Table 72. Teva Business Overview Table 73. Teva Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Teva Therapeutic Peptide Product Portfolio Table 75. Teva Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sanofi Therapeutic Peptide Product Portfolio Table 80. Sanofi Recent Development Table 81. Johnson and Johnson Company Information Table 82. Johnson and Johnson Business Overview Table 83. Johnson and Johnson Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Johnson and Johnson Therapeutic Peptide Product Portfolio Table 85. Johnson and Johnson Recent Development Table 86. Novartis Company Information Table 87. Novartis Business Overview Table 88. Novartis Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Novartis Therapeutic Peptide Product Portfolio Table 90. Novartis Recent Development Table 91. Novo Nordisk Company Information Table 92. Novo Nordisk Business Overview Table 93. Novo Nordisk Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novo Nordisk Therapeutic Peptide Product Portfolio Table 95. Novo Nordisk Recent Development Table 96. Merck Company Information Table 97. Merck Business Overview Table 98. Merck Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Merck Therapeutic Peptide Product Portfolio Table 100. Merck Recent Development Table 101. Eli Lilly Company Information Table 102. Eli Lilly Business Overview Table 103. Eli Lilly Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Eli Lilly Therapeutic Peptide Product Portfolio Table 105. Eli Lilly Recent Development Table 106. AbbVie Company Information Table 107. AbbVie Business Overview Table 108. AbbVie Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. AbbVie Therapeutic Peptide Product Portfolio Table 110. AbbVie Recent Development Table 111. AstraZeneca Company Information Table 112. AstraZeneca Business Overview Table 113. AstraZeneca Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. AstraZeneca Therapeutic Peptide Product Portfolio Table 115. AstraZeneca Recent Development Table 116. Ipsen Company Information Table 117. Ipsen Business Overview Table 118. Ipsen Therapeutic Peptide Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Ipsen Therapeutic Peptide Product Portfolio Table 120. Ipsen Recent Development Table 121. Key Raw Materials Table 122. Raw Materials Key Suppliers Table 123. Therapeutic Peptide Distributors List Table 124. Therapeutic Peptide Customers List Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Therapeutic Peptide Product Image Figure 2. Global Therapeutic Peptide Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Peptide Sales Value (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Peptide Sales (2021-2032) & (K Units) Figure 5. Global Therapeutic Peptide Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Therapeutic Peptide Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Injection Image Figure 11. Other Image Figure 12. Global Therapeutic Peptide Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Therapeutic Peptide Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Therapeutic Peptide Sales Volume Share by Type (2021-2032) Figure 15. Global Therapeutic Peptide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Therapeutic Peptide Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Therapeutic Peptide Sales Value Share by Type (2021-2032) Figure 18. Central Nervous System Image Figure 19. Metabolic Disorders Image Figure 20. Cancer Image Figure 21. Other Image Figure 22. Global Therapeutic Peptide Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Therapeutic Peptide Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Therapeutic Peptide Sales Volume Share by Application (2021-2032) Figure 25. Global Therapeutic Peptide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Therapeutic Peptide Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Therapeutic Peptide Sales Value Share by Application (2021-2032) Figure 28. Global Therapeutic Peptide Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Therapeutic Peptide Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Therapeutic Peptide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Therapeutic Peptide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Therapeutic Peptide Sales Value (2021-2032) & (US$ Million) Figure 33. North America Therapeutic Peptide Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Therapeutic Peptide Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Therapeutic Peptide Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Therapeutic Peptide Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Therapeutic Peptide Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Therapeutic Peptide Sales Value (2021-2032) & (US$ Million) Figure 39. South America Therapeutic Peptide Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Therapeutic Peptide Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Therapeutic Peptide Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Therapeutic Peptide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Therapeutic Peptide Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Therapeutic Peptide Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
  • Other
Applications
  • Central Nervous System
  • Metabolic Disorders
  • Cancer
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • AbbVie
  • AstraZeneca
  • Ipsen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Therapeutic Peptide Sales Value (2021-2032)
  4. 1.2.2 Global Therapeutic Peptide Sales Volume (2021-2032)
  5. 1.2.3 Global Therapeutic Peptide Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Therapeutic Peptide Market Dynamics
  1. 2.1 Therapeutic Peptide Industry Trends
  2. 2.2 Therapeutic Peptide Industry Drivers
  3. 2.3 Therapeutic Peptide Industry Opportunities and Challenges
  4. 2.4 Therapeutic Peptide Industry Restraints
3 Therapeutic Peptide Market by Company
  1. 3.1 Global Therapeutic Peptide Company Revenue Ranking in 2025
  2. 3.2 Global Therapeutic Peptide Revenue by Company (2021-2026)
  3. 3.3 Global Therapeutic Peptide Sales Volume by Company (2021-2026)
  4. 3.4 Global Therapeutic Peptide Average Price by Company (2021-2026)
  5. 3.5 Global Therapeutic Peptide Company Ranking (2024-2026)
  6. 3.6 Global Therapeutic Peptide Company Manufacturing Base and Headquarters
  7. 3.7 Global Therapeutic Peptide Company Product Type and Application
  8. 3.8 Global Therapeutic Peptide Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Therapeutic Peptide Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Therapeutic Peptide Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Therapeutic Peptide Market by Type
  1. 4.1 Therapeutic Peptide Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.1.3 Other
  5. 4.2 Global Therapeutic Peptide Sales Volume by Type
  6. 4.2.1 Global Therapeutic Peptide Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Therapeutic Peptide Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Therapeutic Peptide Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Therapeutic Peptide Sales Value by Type
  10. 4.3.1 Global Therapeutic Peptide Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Therapeutic Peptide Sales Value by Type (2021-2032)
  12. 4.3.3 Global Therapeutic Peptide Sales Value Share by Type (2021-2032)
5 Therapeutic Peptide Market by Application
  1. 5.1 Therapeutic Peptide Application Introduction
  2. 5.1.1 Central Nervous System
  3. 5.1.2 Metabolic Disorders
  4. 5.1.3 Cancer
  5. 5.1.4 Other
  6. 5.2 Global Therapeutic Peptide Sales Volume by Application
  7. 5.2.1 Global Therapeutic Peptide Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Therapeutic Peptide Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Therapeutic Peptide Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Therapeutic Peptide Sales Value by Application
  11. 5.3.1 Global Therapeutic Peptide Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Therapeutic Peptide Sales Value by Application (2021-2032)
  13. 5.3.3 Global Therapeutic Peptide Sales Value Share by Application (2021-2032)
6 Therapeutic Peptide Regional Sales and Value Analysis
  1. 6.1 Global Therapeutic Peptide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Peptide Sales by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Peptide Sales by Region: 2021-2026
  4. 6.2.2 Global Therapeutic Peptide Sales by Region (2027-2032)
  5. 6.3 Global Therapeutic Peptide Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Therapeutic Peptide Sales Value by Region (2021-2032)
  7. 6.4.1 Global Therapeutic Peptide Sales Value by Region: 2021-2026
  8. 6.4.2 Global Therapeutic Peptide Sales Value by Region (2027-2032)
  9. 6.5 Global Therapeutic Peptide Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Therapeutic Peptide Sales Value (2021-2032)
  12. 6.6.2 North America Therapeutic Peptide Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Therapeutic Peptide Sales Value (2021-2032)
  15. 6.7.2 Europe Therapeutic Peptide Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Therapeutic Peptide Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Therapeutic Peptide Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Therapeutic Peptide Sales Value (2021-2032)
  21. 6.9.2 South America Therapeutic Peptide Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Therapeutic Peptide Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Therapeutic Peptide Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Peptide Country-level Sales and Value Analysis
  1. 7.1 Global Therapeutic Peptide Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Therapeutic Peptide Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Therapeutic Peptide Sales by Country (2021-2032)
  4. 7.3.1 Global Therapeutic Peptide Sales by Country (2021-2026)
  5. 7.3.2 Global Therapeutic Peptide Sales by Country (2027-2032)
  6. 7.4 Global Therapeutic Peptide Sales Value by Country (2021-2032)
  7. 7.4.1 Global Therapeutic Peptide Sales Value by Country (2021-2026)
  8. 7.4.2 Global Therapeutic Peptide Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Therapeutic Peptide Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Therapeutic Peptide Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Therapeutic Peptide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Therapeutic Peptide Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Therapeutic Peptide Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Therapeutic Peptide Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson and Johnson
  20. 8.4.1 Johnson and Johnson Company Information
  21. 8.4.2 Johnson and Johnson Business Overview
  22. 8.4.3 Johnson and Johnson Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson and Johnson Therapeutic Peptide Product Portfolio
  24. 8.4.5 Johnson and Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Therapeutic Peptide Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Novo Nordisk
  32. 8.6.1 Novo Nordisk Company Information
  33. 8.6.2 Novo Nordisk Business Overview
  34. 8.6.3 Novo Nordisk Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novo Nordisk Therapeutic Peptide Product Portfolio
  36. 8.6.5 Novo Nordisk Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck Therapeutic Peptide Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Therapeutic Peptide Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 AbbVie
  50. 8.9.1 AbbVie Company Information
  51. 8.9.2 AbbVie Business Overview
  52. 8.9.3 AbbVie Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie Therapeutic Peptide Product Portfolio
  54. 8.9.5 AbbVie Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Therapeutic Peptide Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Ipsen
  62. 8.11.1 Ipsen Company Information
  63. 8.11.2 Ipsen Business Overview
  64. 8.11.3 Ipsen Therapeutic Peptide Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Ipsen Therapeutic Peptide Product Portfolio
  66. 8.11.5 Ipsen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Therapeutic Peptide Value Chain Analysis
  2. 9.1.1 Therapeutic Peptide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Therapeutic Peptide Sales Mode & Process
  6. 9.2 Therapeutic Peptide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Therapeutic Peptide Distributors
  9. 9.2.3 Therapeutic Peptide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst